RESEARCH
Research Grants
In the world of pulmonary hypertension, the word "research" is filled with hope, potential, and excitement. It holds the key to a better understanding of the illness, leading to the development of novel therapies, robust treatments, and more sophisticated tools to care for patients. Research also holds the promise of a better and longer life, better management of symptoms, and ultimately a cure. ​
Wilma Shastry Pulmonary Arterial Hypertension Research Awards
New catalyst grants for researchers are available from PHA Canada in partnership with the Canadian Lung Association. The Wilma Shastry Pulmonary Arterial Hypertension Research Award competition promotes innovative research related to the diagnosis, treatment, and/or mechanism of disease for people living with pulmonary arterial hypertension (PAH).
Catalyst grants are scalable research projects that can include pilot studies, feasibility studies, or translational studies. Research projects must be new and not the continuation of an existing project. Proposals should be creative and with the potential to benefit people living with PAH. The scope of the research proposal is restricted to PAH diagnosis, treatment, biology, and respiratory health.
​
Although the long-term goals for a project may extend beyond the means and timeline of this grant, the results of catalyst projects should enable the development of funding proposals that are eligible for submission to national or international peer-reviewed competitions within 1 year after the end of the catalyst award period.
The total funding amount available for the 2026 competition is $40,000. Two awards will be offered to the highest-ranking candidates chosen by the Review Committee. The application deadline is April 13, 2026 at 16:00 Eastern time.
The funding is for one year and is non-renewable.